ClinicalTrials.gov record
Completed Phase 4 Interventional

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

ClinicalTrials.gov ID: NCT00366002

Public ClinicalTrials.gov record NCT00366002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy

Study identification

NCT ID
NCT00366002
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

  • Darifenacin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2006
Primary completion
Not listed
Completion
Aug 31, 2007
Last update posted
Jan 14, 2008

2006 – 2007

United States locations

U.S. sites
82
U.S. states
25
U.S. cities
82
Facility City State ZIP Site status
Investigative Site Birmingham Alabama 35242
Investigative Site Chandler Arizona 85224
Investigative Site Mesa Arizona 85206
Investigative Site Sierra Vista Arizona 85635
Investigative Site Tempe Arizona 85282
Investigative Site Atherton California 94027
Investigative Site Los Angeles California 90048
Investigative Site Newport Beach California 92660
Investigative Site San Diego California 92108
Investigative Site Temecula California 92591
Investigative Site Torrance California 90505
Investigative Site Upland California 91786
Investigative Site Aurora Colorado 80012
Investigative Site Littleton Colorado 80122
Investigative Site Wheat Ridge Colorado 80033
Investigative Site Hollywood Florida 33021
Investigative Site New Smyrna Beach Florida 32168
Investigative Site Ocala Florida 34474
Investigative Site Orlando Florida 32803
Investigative Site Sarasota Florida 34237
Investigative Site Tampa Florida 33607
Investigative Site West Palm Beach Florida 33409
Investigative Site Weston Florida 33331
Investigative Site Alpharetta Georgia 30005
Investigative Site Atlanta Georgia 30342
Investigative Site Marietta Georgia 30060
Investigative Site Roswell Georgia 30076
Investigative Site Snellville Georgia 30078
Investigative Site Melrose Park Illinois 60160
Investigative Site O'Fallon Illinois 62269
Investigative Site Peoria Illinois 61615
Investigative Site Evansville Indiana 47714
Investigative Site Greenwood Indiana 46143
Investigative Site Topeka Kansas 66606
Investigative Site Milford Massachusetts 01757
Investigative Site Watertown Massachusetts 02472
Investigative Site Flint Michigan 48507
Investigative Site Saint Joseph Michigan 49085
Investigative Site Chesterfield Missouri 63017
Investigative Site Kansas City Missouri 64114
Investigative Site St Louis Missouri 63136
Investigative Site Lincoln Nebraska 68510
Investigative Site Omaha Nebraska 68114
Investigative Site Lawrenceville New Jersey 08648
Investigative Site West Orange New Jersey 07052
Investigative Site Albany New York 12206
Investigative Site Garden City New York 11530
Investigative Site Latham New York 12110
Investigative Site Mineola New York 11501
Investigative Site New Hartford New York 13413
Investigative Site Poughkeepsie New York 12601
Investigative Site Troy New York 12180
Investigative Site Williamsville New York 14221
Investigative Site Burlington North Carolina 27215
Investigative Site Charlotte North Carolina 28209
Investigative Site Concord North Carolina 28205
Investigative Site Hickory North Carolina 28601
Investigative Site High Point North Carolina 27262
Investigative Site Salisbury North Carolina 28144
Investigative Site Winston-Salem North Carolina 27103
Investigative Site Cincinnati Ohio 45212
Investigative Site Bethany Oklahoma 73008
Investigative Site Edmond Oklahoma 73034
Investigative Site Portland Oregon 97205
Investigative Site Springfield Oregon 97477
Investigative Site Pittsburgh Pennsylvania 15213
Investigative Site Amarillo Texas 79106
Investigative Site Corsicana Texas 75110
Investigative Site Dallas Texas 75231
Investigative Site Fort Worth Texas 76104
Investigative Site Houston Texas 77005
Investigative Site Lake Jackson Texas 77566
Investigative Site Bountiful Utah 84010
Investigative Site Salt Lake City Utah 84124
Investigative Site Sandy City Utah 84070
Investigative Site Richmond Virginia 23294
Investigative Site Everett Washington 98208
Investigative Site Lakewood Washington 98499
Investigative Site Mountlake Terrace Washington 98233
Investigative Site Seattle Washington 98101
Investigative Site Vancouver Washington 98664
Investigative Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00366002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 14, 2008 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00366002 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →